Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y₁₂ receptor between selatogrel and oral P2Y₁₂ antagonists.

ABSTRACT: Selatogrel is a potent and reversible P2Y₁₂ receptor antagonist developed for subcutaneous self-administration by patients with suspected acute myocardial infarction. After single-dose emergency treatment with selatogrel, patients are switched to long-term treatment with oral P2Y₁₂ receptor antagonists. Selatogrel shows rapid onset and offset of inhibition of platelet aggregation (IPA) to overcome the critical initial time after acute myocardial infarction. Long-term benefit is provided by oral P2Y₁₂ receptor antagonists such as clopidogrel, prasugrel, and ticagrelor. A population pharmacokinetic (PK)/pharmacodynamic (PD) model based on data from 545 subjects in 4 phase I and 2 phase II studies well described the effect of selatogrel on IPA alone and in com

SUBMITTER: Henrich A 

PROVIDER: S-EPMC8302241 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature